Printer Friendly

CEL-SCI announces the development and patenting of a new platform technology to treat immune system-based diseases.

CEL-SCI CORPORATION (Vienna, VA) announced the development and patenting of a new platform technology for the treatment of a number of major diseases including autoimmune disease, asthma, allergy and transplant rejection. CEL-SCI recently received a notice of allowance from the United States patent office protecting this technology.

This breakthrough T-cell modulation platform technology is called "AdapT," which stands for "Antigen Directed Apoptosis." AdapT technology uses proprietary two-peptide molecular constructs to selectively cause the death of only those immune T-cells that are involved in autoimmune disease, asthma, allergy, and transplant rejection, by having these disease causing T-cells undergo apoptosis (programmed cell death) and anergy (a state of immune unresponsiveness).

It has been well established in the scientific literature that at least two signals are required for T-cell activation and that, if only one signal is supplied to T-cells without the ability of the same T-cells to receive a second activation signal, the T-cells undergo "programmed cell death." The AdapT molecular constructs capitalize on this well known principle and "work" by engaging the antigen-specific T-cell receptor with one of its peptides and, at the same time, block and inhibit the second signal needed for the full activation of these disease causing T-cells. This single engagement (T-cell receptor occupation), in the absence of the required "second signal" for T- cell activation, causes these antigen-specific disease causing T-cells to self-destruct and die, thereby leading to the treatment and prevention of these diseases.

The advantage of the AdapT technology derives from its ability to selectively remove the disease causing T-cell clones from the host (humans and animals) following the administration of the AdapT construct(s). Current treatments of these diseases generally utilize non-specific immunosuppressants or immunomodulatory compounds or cytokines. The use of an antigen-specific technology to regulate the immune response and the T-cells causing disease has a distinct advantage over the use of non-specific immunosuppressants because the AdapT technology should limit or even eliminate the unwanted side effects of the currently available immunosuppressant drugs.

Dr. Eyal Talor, Senior Vice President of Research and Manufacturing at CEL-SCI and the inventor of this technology said, "The AdapT technology provides for a way to target only those T-cells that cause disease. This new approach should give us the ability to markedly decrease or completely retard the disease process, and at the same time avoid the negative effects on the healthy part of the immune system -- thus, treating the disease and at the same time keeping the rest of the immune response intact."

CEL-SCI is developing new immune system based treatments for cancer and infectious diseases. The company has operations in Vienna, Virginia and Baltimore, Maryland. The company's lead product Multikine is cleared to enter global Phase III clinical trials in advanced primary head and neck cancer patients. CEL-SCI's other products, which are currently in pre-clinical stage and have been funded with United States government support, have shown protection against a number of diseases in animal tests and are currently being tested against diseases associated with bio-defense and avian flu.

CEL-SCI Corporation

COPYRIGHT 2006 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Dec 1, 2006
Previous Article:Reliant files patent infringement lawsuit against Par.
Next Article:Patent granted to ScinoPharm for production of irinotecan intermediate.

Related Articles
CEL-SCI obtains three new HIV patents.
Coley receives dendritic cell patent.
Mymetics patents HIV treatment involving retrovirus immune response.
BioVex signs exclusive licence to use key antigens in vaccine.
Viragen granted United States patent for manufacture of Multiferon.
CEL-SCI receives United States patent on pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy.
CEL-SCI receives United States patent for use of peptide vaccine technology for autoimmune conditions and allergies.
CEL-SCI files patent application for prevention/treatment of avian flu.
CEL-SCI announces issuance of United States patent for new platform technology to treat immune system-based diseases.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters